anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This will be a prospective up/down dosage study. After obtaining informed consent, eligible participants will be part of an up/down dose titration study. This first phase of our study will be conducted using intrathecal (spinal) hydromorphone to determine an appropriate dose range for our study population. Study drug dose will initially be 40 mcg. The only deviation from the current standard of care will be that patients will be given hydromorphone intrathecally instead of morphine. The rest of the care provided will be standard of care and per current practices at VCU labor and delivery floor.
Atherosclerosis is marked with the accumulation of low-density lipoproteins and chronic inflammation. The anti-inflammatory therapies exert protective effects on atherosclerosis. Vasicine is a bioactive alkaloid with anti-inflammatory activity from a medicinal plant in Ayurveda and Unani. In this study, the effects of vasicine were evaluated on atherosclerosis in vivo and in vitro. The results showed that vasicine alleviated atherosclerotic lesions and regulated the lipid synthesis by reducing the levels of TC, TG, LDL-C and inhibiting the expresses of scavenger receptors (SR-A, CD36 and LOX-1) to inhibit foam cell formations. And vasicine decreased the levels of IL-1β, IL-6, MCP-1, and TNF-α to modulate inflammatory response. Besides, vasicine downregulated MAPK and PI3K/AKT/mTOR pathway to activated autophagy, which inhibited the procession of atherosclerosis.
Following the final randomized visit, interested participants were prescribed 10mg of methylphenidate twice daily, increased to 20mg of methylphenidate twice daily as tolerated. After a four week treatment trial, their scores on the batteries and questionnaires were again assessed.
PURPOSE:To obtain the titled substance from the cultured product obtained by the cultivation of microorganisms belonging to Actinoplanes genus and capable of producing the titled substance, and to use the titled substance as an antibacterial agent and an agent for promoting the host resistance. CONSTITUTION:Microorganisms belonging to Actinoplanes genus and capable of producing isohematinic acid of formula, e.g. Actinoplanes sp. SANK61681 strain, are cultured in a medium containing known nutrients for actinomycetes, e.g. glucose, glycerin, soybean oil, corn steep liquor, peptone, meat extract, inorganic salts, etc. at 24-30 deg.C and nearly neutral pH condition. After the cultivation, the microbial cells are separated from the medium by filtration, and the objective isohematinic acid is separated from the filtrate with e.g. adsorbent, etc. The obtained isohematinic acid is used as an antibacterial agent or an agent for promoting the host resistance.
PROBLEM TO BE SOLVED: To obtain a granular composition containing a solid vitamin E, a solid vitamin C and a sucrose fatty acid ester and having fluidity and safety suitable for wet granulation and to provide a safe method for producing the composition. SOLUTION: This composition is obtained by formulating a dispersion prepared by dispersing a solid vitamin into an aqueous solution or an aqueous dispersion of a sucrose fatty acid ester with a solid vitamin C and/or another component. The amount of the solid vitamin E is 0.1-10 pts.wt. based on 100 pts.wt. of the composition, that of the sucrose fatty acid ester is 2-25 pts.wt. based on 100 pts.wt. of the vitamin E and the amount of the solid vitamin C is 10-90 pts.wt. based on 100 pts.wt. of the composition.
The invention provides a compound preparation for treating influenza and a preparation method thereof. The compound preparation is prepared by mixing the first medicinal powder, the second medicinal powder, the dry extract of the medicinal materials and the essential oil of the medicinal materials to prepare pellets, and preparing the pellets into granules, capsules or tablets. The first medicinal powder and the second medicinal powder are respectively prepared by pulverizing and mixing the first component and the second component. The dry extract of the medicinal materials is prepared by extracting and concentrating the third component. The medicinal material essential oil is prepared from the fourth component. The first component comprises acetaminophen; the second component comprises balloonflower root, calcium carbonate and buffalo horn; the third component comprises semen Sojae Preparatum, flos Lonicerae, fructus Arctii, fructus forsythiae, folium Bambusae, rhizoma Phragmitis and Coicis semen; the fourth component comprises herba Schizonepetae and Mentholum. The compound preparation is prepared into pellets, so that the stability of the compound preparation is improved, the toxic and side effects are reduced, and the compound preparation can play a role in controlled release. And secondly, the acetaminophen is wrapped on the outer surface of the traditional Chinese medicine components, so that the antipyretic and analgesic effects can be quickly exerted, and the bioavailability is improved.
Variable practice involving the practice of several variations of motor skill benefits learning differently than practice in constant conditions, i.e., practice that involves only one variation of a skill. The variable practice results in better retention and transfer. The performance of a skill practiced in variable conditions is more accurate and stable. In contrast, practicing only one variation of a skill better refines the recall schema. It means that the motor program (which serves as an "example" while executing a movement) is developed better. The trained variation of a skill (in constant practice), produces an advantage in performance compared to the same variation of the skill that was practiced in variable conditions (assuming that variable and constant practice had similar capacity).

This finding has an important implication for those who want to master their skills and it does not matter whether this skill refers to sport, driving, piloting, or rehabilitation. If one wants to be good at performing only one variation of a skill, one should practice in constant conditions, whereas if one wants to be good in more than one variation of skill and wants to generalize the experience to novel situations an individual should practice in variable conditions. As one can see, this implication is practical, although the mechanisms underlying this distinction and differences are unknown.

On the other hand, it is unquestioned today that learning new motor skills dynamically changes brain, i.e., brain is neuroplastic. The neuroplasticity of the brain is specifically conspicuous in the progression of motor learning. As it was reported in previous research, cortico-striatal and cortico-cerebellar systems play an important role in motor skill acquisition. However, both of these systems differ in terms of the role they play as learning progresses. Cortico-striatal system (associative/premotor brain regions) is primarily engaged in the initial phase of learning, i.e., in cognitive functioning and sensory processing. Cortico-cerebellar system (sensorimotor network) is becoming more active in the later phase of motor learning. However, none of the previous research focused on what role these systems play in learning under different conditions and how the different roles the systems may play affect structural neuroplasticity, including grey and white matter.

It may be also interesting to look at the functional neuroplasticity. A lesser degree of cognitive involvement during the execution of movements may be associated with lower activation in the sensorimotor cortex. On the other hand, increased cognitive involvement may be expected in variable conditions due to, e.g., stimulus identification or decision making. Therefore, the assumption that decreased cognitive involvement and, as a result, decreased prefrontal cortex activation in constant practice conditions sounds reasonable. Moreover, it may be hypothesized that practicing and learning in constant conditions will be characterized by lower sensorimotor cortex activation since there will be decreased control during the motor performance, which leads to more adaptive motor performance.
ONCOS-102 will be administered in a priming cycle (Cycle 1) comprising injections on Days 1, 4, 8 and 36, followed by two treatment cycles at intervals of 6 weeks (Cycle 2, Day 78 and Cycle 3, Day 120). Pre-treatment with an i.v. bolus of cyclophosphamide (CPO) will be given 1 to 3 days before the first administration of ONCOS-102 (Cycle 1, Day 1) and before administration of Cycle 2 of ONCOS-102 (Day 78). Patients will also receive pemetrexed/cisplatin (carboplatin) in 21-day cycles starting on Day 22 and continuing as applicable during the study period of 6 cycles of pemetrexed/cisplatin (carboplatin) in combination with ONCOS-102.
Participants randomized to this group will be enrolled to a 150 min/week structured and supervised exercise training. The program consists of 3 sessions in a week, each of these lasting 50 minutes. The session will be composed of aerobic training (25 minutes at 60-75% of HRmax) and strength training (25 minutes, 8 whole-body exercises at up to 8-12 maximal repetitions).
One of the most highly effective preventive measures a mother can make in protecting the health of her infant and herself is to breastfeed. Despite extensive research on breast-milk, limited information beyond basic micro/macronutrient composition currently exists in the literature. Breast-milk is a complex, non-uniform biological substance. In prior studies the PI has shown significant associations be-tween non-nutritive constituents in breast-milk (e.g. IL-6, TNF-α, insulin, leptin) and body composition in infants starting at 4wks of age. The putative causal influence of breastfeeding reducing obesity is mixed with no clear probative evidence showing causal pathways. Despite many studies in this area, there are no detailed studies that have examined the potential modifying role of maternal diet, especially one high in sugars on the compositional makeup of the three largest breast-milk sugars (glucose, galactose and lactose) with none to date looking at fructose. Animal models have demonstrated that the obesogenic effect of maternal fructose consumption is transmitted to offspring via breast-milk with fructose-fed lactating dams producing offspring with double fasting insulin levels compared to control pups. This is relevant in humans because of the increase in dietary sugar consumption that has occurred in the population.

A mother/infant cohort (n=37) has been established with detailed infant phenotypic body composition (dual-energy X-ray absorptiometry) and detailed breast-milk analysis (insulin, leptin, IL-6, TNF-α but no milk sugars other than glucose) in exclusively breast feeding mothers varying widely in BMI (19 to 44 kg/m2). Sampling of breast-milk and infant body composition occurred at both 4 and 24wks. As a proof of concept, fructose was detected in breast-milk from 9 of these mothers which was significantly related to infant body fat, which is a novel finding to date and has never been reported in the literature. Building upon this prior work this study will determine the concentration and pharmacokinetics of breast-milk sugars after a test beverage is consumed.
PURPOSE OF REVIEW: Chronic spontaneous urticaria (CSU) patients sometimes do not respond to second-generation antihistamine, and 10-50% patients do not even respond to four-fold the usual dose of nonsedating H1 antihistamine, which further leads to repeated courses of oral corticosteroids to abate the symptoms. There are third-line agents approved by EAACI guidelines, which include omalizumab and cyclosporine. Certain patients are even resistant to the third-line agents. In this review, various other treatment options will be discussed in patients of refractory CSU.
RECENT FINDINGS: Recently, we demonstrated azathioprine as a possible third-line option, which was found noninferior to cyclosporine in antihistamine refractory CSU. There have been trials, studies, case series and reports, which suggest other putative options for refractory CSU management.
SUMMARY: Studies on the management of refractory CSU are accumulating thereby expanding the armamentarium of dermatologists and allergologist against difficult-to-treat urticaria patients.
A smart pill organizer device for use in a networked computer system to wirelessly monitor a patient's adherence to medication doses, sends alerts when missed, and order refills as needed. The device is a container comprising: a tray of removable dose units tagged with a unique identifier assigned to a patient. The tag may comprise a scannable barcode, and the scanner may be part of the device, or kit. The device further comprises computer components and wireless transmitters, and one or more electromagnetic sensors, e.g. positioned beneath the dose units, to detect when a dose is taken, and transmit the information to a remote server comprising a patient database record. When a dose is missed, an alert is sent to one or more third party electronic computing devices (e.g. patient's, doctor's, pharmacy, caregiver's, etc.). The dose units are filled automatedly with a patient's prescription by a pharmaceutical robotic system.
<P>PROBLEM TO BE SOLVED: To provide a grafting material used by being locally applied for the purpose of improvement in bone quality.  <P>SOLUTION: The grafting material used by being locally applied for the purpose of the improvement in bone quality comprises a cell selected from the group consisting of an embryonic stem cell (ES cell), a mesenchymal stem cell (MSC), an osteoblast, a preosteoblast, a chondrocyte and a cell having a capability of bone formation. The grafting material can be used as a bone improver against bone quality decline for instance. Further, it is preferable that the grafting material contains a scaffold, amphiphilic peptide and platelet-rich plasma (PRP), etc. The grafting material can be used for the prevention and treatment of bone quality degradation diseases including osteoporosis of Homo sapiens and non-Homo-sapiens animals (preferably Homo sapiens), for instance.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The invention relates to a traditional Chinese medicine composition for treating gastrointestinal failure of multi-organ dysfunction syndrome and a preparation thereof, which belong to the filed of traditional Chinese medicines. The traditional Chinese medicine composition for treating the multi-organ dysfunction is prepared by extracting the following raw materials by weight proportion: 40-60 parts of officinal magnolia bark, 20-30 parts of immature bitter orange, 10-20 parts of rhubarb, 20-30 parts of costustoot, 20-30 parts of dried tangerine peel, 40-60 parts of membranous milkvetch root,10-20 parts of largehead atractylodes rhizome and 10-20 parts of Chinese angelica. The traditional Chinese medicine composition has the advantage that: the traditional Chinese medicine composition isan experience formula which is summed up by years of clinical practices of our hospital. The formula has no highly toxic drug and no compatibility contraindication, and the using amount is in the stipulated scope of pharmacopoeia. The long-term clinical application does not find the toxic and adverse reactions, and the preparation of the formula has no toxic reaction by the animal formulation toxicity test. The traditional Chinese medicine composition is designed against the MODS bowel qi obstruction, and the practices show that the traditional Chinese medicine composition can effectively improve the rate of successful rescue of MODS, reduce the mortality rate of MODS to 28.4 percent as the lowest and reach the international advanced level.
Thirty patients in this group will receive infusion of dexmedetomidine (0,5 mcg/kg/min). After 15 min of the beginning of this infusion they will start in the general anesthesia induction.
BACKGROUND AND OBJECTIVES: Vascular risk factors (VRFs) and cerebral small vessel disease (cSVD) are common in patients with Alzheimer disease (AD). It remains unclear whether this coexistence reflects shared risk factors or a mechanistic relationship and whether vascular and amyloid pathologies have independent or synergistic influence on subsequent AD pathophysiology in preclinical stages. We investigated links between VRFs, cSVD, and amyloid levels (Aβ1-42) and their combined effect on downstream AD biomarkers, that is, CSF hyperphosphorylated tau (P-tau181), atrophy, and cognition.
METHODS: This retrospective study included nondemented participants (Clinical Dementia Rating < 1) from the European Prevention of Alzheimer's Dementia (EPAD) cohort and assessed VRFs with the Framingham risk score (FRS) and cSVD features on MRI using visual scales and white matter hyperintensity volumes. After preliminary linear analysis, we used structural equation modeling (SEM) to create a "cSVD severity" latent variable and assess the direct and indirect effects of FRS and cSVD severity on Aβ1-42, P-tau181, gray matter volume (baseline and longitudinal), and cognitive performance (baseline and longitudinal).
RESULTS: A total cohort of 1,592 participants were evaluated (mean age = 65.5 ± 7.4 years; 56.16% F). We observed positive associations between FRS and all cSVD features (all p < 0.05) and a negative association between FRS and Aβ1-42 (β = -0.04 ± 0.01). All cSVD features were negatively associated with CSF Aβ1-42 (all p < 0.05). Using SEM, the cSVD severity fully mediated the association between FRS and CSF Aβ1-42 (indirect effect: β = -0.03 ± 0.01), also when omitting vascular amyloid-related markers. We observed a significant indirect effect of cSVD severity on P-tau181 (indirect effect: β = 0.12 ± 0.03), baseline and longitudinal gray matter volume (indirect effect: β = -0.10 ± 0.03; β = -0.12 ± 0.05), and baseline cognitive performance (indirect effect: β = -0.16 ± 0.03) through CSF Aβ1-42.
DISCUSSION: In a large nondemented population, our findings suggest that cSVD is a mediator of the relationship between VRFs and CSF Aβ1-42 and affects downstream neurodegeneration and cognitive impairment. We provide evidence of VRFs indirectly affecting the pathogenesis of AD, highlighting the importance of considering cSVD burden in memory clinics for AD risk evaluation and as an early window for intervention. These results stress the role of VRFs and cerebrovascular pathology as key biomarkers for accurate design of anti-amyloid clinical trials and offer new perspectives for patient stratification.
PURPOSE: To perform the determination of the location of a neoplastic tissue or discovery of the hidden tumor of a patient during an operation in a short period of time by a new method utilizing a somatostain congener. CONSTITUTION: This new method for detecting and differentiating neoplastic tissue includes first the administration of unlabelled somatostatin congener to a patient suspected to have a neoplastic tissue such as a tumor, in an amount of inhibiting a biological marker. Next, the biological marker related to the above neoplastic tissue is monitored, and whether the administered somatostatin congener reduced the presence of the marker in the patient or not is measured. Then, in the case that the presence of the marker is reduced, i.e., the somatostatin receptor binds with the neoplastic tissue, a radiolabelled somatostatin congener is administered. Finally, a tissue showing an elevation of the radioactivity level is located by using a radiation detecting probe.  Further, as the somatostation congener, a lantreotide or Tyr3 -octreotide are preferable, and as the radiolabelling agent,<125> I is preferable.
PURPOSE:To safely improve treatment by containing a monoclonal antibody specific for endoserines as an active ingredient. CONSTITUTION:The thoracic aorta of a Wistar strain rat is treated to provide an endoserien-1-thyroglobulin conjugant (A). A rabbit is then immunized with the ingredient (A) to increase the antibody value and afford an antiserum (B). (NH4)2SO4 is subsequently added to the ingredient (B) and the resultant precipitates are then dialyzed with a physiological NaCl solution at about pH7.4 to afford a conjugant of the thyroglobulin and Cellulofine(R). The obtained ingredient (C) is then subjected to affinity column chromatography and unadsorbed components passing therethrough without adsorption are subjected to affinity column chromatography of a conjugant of protein A and Cellulofine(R) and adsorbed thereon. Thereby, adsorbed substances (D) are obtained. The ingredient (D) is subsequently eluted with a buffer solution containing NaCl, etc., to afford an eluate, which is dialyzed and subsequently lyophilized to produce treating agent, containing an antibody (IgG) specific for endoserine-1 and useful for diseases caused by vascular contraction.
Eligible patients will receive matching placebo in addition to their stable dose of insulin with or without metformin. One tablet should be taken twice daily as one tablet before breakfast meal and one tablet before the evening meal for 24 weeks.
BACKGROUND AND OBJECTIVES: Progression independent of relapse activity (PIRA) is a crucial determinant of overall disability accumulation in multiple sclerosis (MS). Accelerated brain atrophy has been shown in patients experiencing PIRA. In this study, we assessed the relation between PIRA and neurodegenerative processes reflected by (1) longitudinal spinal cord atrophy and (2) brain paramagnetic rim lesions (PRLs). Besides, the same relationship was investigated in progressive MS (PMS). Last, we explored the value of cross-sectional brain and spinal cord volumetric measurements in predicting PIRA.
METHODS: From an ongoing multicentric cohort study, we selected patients with MS with (1) availability of a susceptibility-based MRI scan and (2) regular clinical and conventional MRI follow-up in the 4 years before the susceptibility-based MRI. Comparisons in spinal cord atrophy rates (explored with linear mixed-effect models) and PRL count (explored with negative binomial regression models) were performed between: (1) relapsing-remitting (RRMS) and PMS phenotypes and (2) patients experiencing PIRA and patients without confirmed disability accumulation (CDA) during follow-up (both considering the entire cohort and the subgroup of patients with RRMS). Associations between baseline MRI volumetric measurements and time to PIRA were explored with multivariable Cox regression analyses.
RESULTS: In total, 445 patients with MS (64.9% female; mean [SD] age at baseline 45.0 [11.4] years; 11.2% with PMS) were enrolled. Compared with patients with RRMS, those with PMS had accelerated cervical cord atrophy (mean difference in annual percentage volume change [MD-APC] -1.41; p = 0.004) and higher PRL load (incidence rate ratio [IRR] 1.93; p = 0.005). Increased spinal cord atrophy (MD-APC -1.39; p = 0.0008) and PRL burden (IRR 1.95; p = 0.0008) were measured in patients with PIRA compared with patients without CDA; such differences were also confirmed when restricting the analysis to patients with RRMS. Baseline volumetric measurements of the cervical cord, whole brain, and cerebral cortex significantly predicted time to PIRA (all p ≤ 0.002).
DISCUSSION: Our results show that PIRA is associated with both increased spinal cord atrophy and PRL burden, and this association is evident also in patients with RRMS. These findings further point to the need to develop targeted treatment strategies for PIRA to prevent irreversible neuroaxonal loss and optimize long-term outcomes of patients with MS.